AnaBios offers early human insights into the drug development process and is redefining ‘First-in-Human’ studies.
JUN
27
WEBINAR | Human Ventricular Action Potential & E14 Waivers for Novel Drugs
Online
Details:
VP of Research & Development Najah Abi-Gerges, Ph.D. and Derek Leishman, Ph.D., VP of Translational and Qualitative Toxicology at Eli Lilly, will discuss a ventricular action potential assay that can contribute to E14 waiver request data sets.